Daunorubicin 20mg
Product Overview
| Generic Name | Daunorubicin 20mg |
| Brand Name(s) | Daunohal; Cerubidine; Daunomycin; Daunotec; Dauneon; Daunomac; Vyxeos (liposomal form); DaunoXome |
| Category | Antineoplastic / Cancer |
| Form | Lyophilized powder for IV injection; vial form |
| Strength | 20 mg per vial (≈21.4 mg hydrochloride salt equivalent) |
| Therapeutic Class | Anthracycline topoisomerase II inhibitor |
| ATC Code | L01DB07 |
Manufacturing & Regulatory
| Manufacturer | Halsted Pharma, Pfizer/Actavis, Cipla, Neon, Admac |
| GMP Compliance | WHO/cGMP-compliant |
| DMF/CEP | Type II DMFs |
| COFEPRIS | Pending |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 units |
| Shelf Life | 24 Months |
| Storage | 20–25 °C, protect from light; reconstitute prior to administration |
| Incoterms | EXW 30049046 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Provided per batch |
| SDS-Safety Data Sheet (PDF) | Upon Request |
| CTD Summary (PDF) | CTD from originator; generic use abbreviated formats |
Special Notes
Indications & Usage: Daunorubicin is indicated for induction of remission in acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and certain leukemic phases of CML; administered IV under specialist supervision (often combined with cytarabine); liposomal variant (Vyxeos) approved for therapy-related AML or AML with myelodysplasia-related changes; off-label use in Kaposi’s sarcoma; mechanism: DNA intercalation and topoisomerase II inhibition leading to cytotoxicity